AMD

The agency issued approval for Yesafili, from Biocon Biologics, and Opuviz, from Samsung Bioepis and Biogen

For decoding biomarkers, a multistage system is just the beginning

The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March

At the ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Giulia Corradetti, MD about AMD

At this year's ARVO meeting, Ash Abbey, MD, presented 36-month data from the GALE study of pegcetacoplan

Antonio Filipe Macedo, OD, MSc, PhD, speaks about his ARVO presentation on vision-related activity difficulties in patients with neovascular age-related macular degeneration

Susana Chung, OD, PhD, speaks about one of her ARVO presentations and the future of artificial intelligence in eye care

I-SCREEN will bring together 12 institutions across Europe, including Queen’s University Belfast

The European Commission is expected to make a decision about the application before the end of June

Research indicates smoking increases risk of AMD, cataracts and glaucoma

Physicians explore how other specialties adopt and integrate remote monitoring

EODM may be an ideal candidate for development of complement gene therapy due to the high-impact genetic variants

The trial will use vision preservation as a primary outcome measure, according to Annexon

The European Union approval applies to aflibercept 8 mg for treatment of nAMD and DME

The study illustrates efficacy of AVT06 as compared with aflibercept (Eylea) for neovascular age-related macular degeneration

Real-world data from using faricimab to treat neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME)

The study results will help to identify dosing levels for future clinical trials

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD

The company received marketing authorisation approval in the EU earlier this year

The endorsement follows FDA approval in the United States this summer

Peter K. Kaiser, MD, provides an overview of innovative therapies in development for patients with dry age-related macular degeneration.

Arshad M. Khanani, MD, MA, FASRS, highlights the fluid resolution with faricimab and the need for loading doses, especially in high-needs switch patients with nAMD or DME.

Arshad M. Khanani, MD, MA, FASRS, discusses rapid improvement with faricimab in several anatomic parameters in treatment-naïve and previously treated patients with nAMD and DME in the TRUCKEE and TAHOE studies.

Data indicated switching to SB15 from AFL maintained comparable clinical efficacy and safety, confirming biosimilarity between these agents

Case 1 highlights the potential for this treatment for patients with dry AMD with noted letter gains

The 23rd annual EURETINA Congress took place in Amsterdam, the Netherlands. We spoke with Arshad M. Khanani, MD, MA, FASRS, who provided an overview of his presentation, "Emerging therapies for exudative AMD"

Robyn Guymer, MBBS, PhD, Deputy Director, Centre for Eye Research Australia, and Professor of Surgery (Ophthalmology), University of Melbourne, Australia, discussed the study findings at the 23rd annual EURETINA Congress in Amsterdam, the Netherlands

Our team spoke to David Almeida, MD, PhD, MBA about his EURETINA presentation titled, The Real-World Efficacy and Safety of Faricimab in Neovascular AMD: The TRUCKEE Study.

Dr Marco Zarbin presents his talk from the 2023 ASRS annual meeting, where he explores the impact of disease activity criteria on drug durability estimations in clinical trials and includes a comparative analysis across multiple clinical trials in neovascular AMD (age-related macular degeneration).

The diagnostics company is using AI to screen for diabetic retinopathy, glaucoma and age-related macular degeneration